Aarti Pharmalabs
Ticker > Company >

Aarti Pharmalabs share price

Aarti Pharmalabs Ltd.

NSE: AARTIPHARM BSE: 543748 SECTOR: Pharmaceuticals & Drugs  79.25 K   135   41

903.90
-14.65 (-1.59%)
BSE: Today, 02:16 PM

Price Summary

Today's High

₹ 919

Today's Low

₹ 900.5

52 Week High

₹ 971.5

52 Week Low

₹ 550.25

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 8193.06 Cr.

Enterprise Value

₹ 8584.39 Cr.

No. of Shares

9.06 Cr.

P/E

31.34

P/B

4.33

Face Value

₹ 5

Div. Yield

0.55 %

Book Value (TTM)

₹  208.89

CASH

₹ 3.52 Cr.

DEBT

₹ 394.86 Cr.

Promoter Holding

43.72 %

EPS (TTM)

₹  28.84

Sales Growth

17.92%

ROE

14.86 %

ROCE

17.61%

Profit Growth

28.26 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year17.92%
3 Year23.47%
5 Year∞%

Profit Growth

1 Year28.26%
3 Year34.1%
5 Year572.77%

ROE%

1 Year14.86%
3 Year13.6%
5 Year11.21%

ROCE %

1 Year17.61%
3 Year16.59%
5 Year13.17%

Debt/Equity

0.2143

Price to Cash Flow

24.1

Interest Cover Ratio

14.1213

CFO/PAT (5 Yr. Avg.)

0.916213033274686

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 43.72 0.01
Mar 2025 44.29 0.00
Dec 2024 44.66 0.00
Sep 2024 46.10 0.00
Jun 2024 46.46 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 34.0963737099923% for the Past 3 years.
  • The company has shown a good revenue growth of 23.4717496247696% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 14.1213.

 Limitations

  • Promoter pledging has increased from 0% to 0.01% in 1 quarter.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 393.49 377.29 470.95 529.62 375.31
Total Expenditure 309.83 292.52 355.96 386.5 280.18
Operating Profit 83.65 84.77 114.99 143.13 95.13
Other Income 2.11 2.95 11.94 -2.51 1.6
Interest 4.25 5.39 9.7 6.29 6.8
Depreciation 18.29 18.89 21.04 20.83 22.76
Exceptional Items 0 0 0 0 0
Profit Before Tax 63.23 63.43 96.18 113.5 67.17
Tax 16.08 15.6 22.66 24.66 15.95
Profit After Tax 47.14 47.84 73.52 88.85 51.22
Adjusted EPS (Rs) 5.2 5.28 8.11 9.8 5.65

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 0 941.02 1511.25 1502.13 1771.35
Total Expenditure 0 761.24 1202.91 1155.97 1344.81
Operating Profit 0 179.79 308.34 346.16 426.54
Other Income 0 2.51 1.28 11.01 14.49
Interest 0 11.34 20.49 16.63 25.63
Depreciation 0 37.23 55.77 66.01 79.06
Exceptional Items 0 0 0 0 0
Profit Before Tax 0 133.73 233.36 274.52 336.34
Tax 0 27 61.63 73.87 78.99
Net Profit 0 106.73 171.73 200.65 257.35
Adjusted EPS (Rs.) -0.18 4269.05 18.95 22.14 28.39

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 0.25 0.25 45.31 45.31 45.32
Total Reserves -0.02 1284.03 1393.27 1576.15 1798.55
Borrowings 0 0 0 0 103.56
Other N/C liabilities 0 60.88 74.04 119.87 153.85
Current liabilities 0.02 481.67 463.75 555.58 622.33
Total Liabilities 0.25 1826.83 1976.37 2296.91 2723.61
Assets
Net Block 0 701.12 848.4 953.33 1059.32
Capital WIP 0 165.23 62.23 78.5 300.92
Intangible WIP 0 22.14 39.67 58.42 67.77
Investments 0 39.87 42.67 43.83 41.15
Loans & Advances 0 8.21 17.18 28.77 41.63
Other N/C Assets 0 0 0 0 0
Current Assets 0.25 890.27 966.22 1134.06 1212.8
Total Assets 0.25 1826.83 1976.37 2296.91 2723.61
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 0 133.73 233.36 274.52 336.34
Adjustment 0 46.08 76.87 80.71 109.05
Changes in Assets & Liabilities 0 -229.65 -37.61 -124.55 -46.88
Tax Paid 0 -15 -56.73 -46.99 -58.5
Operating Cash Flow 0 -64.84 215.88 183.69 340.01
Investing Cash Flow 0 -133.54 -115.55 -184.4 -419.8
Financing Cash Flow 0 254.63 -156.53 4.4 78.63
Net Cash Flow 0 56.25 -56.2 3.7 -1.16

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 46.46 46.10 44.66 44.29 43.72
aarnav rashesh gogri 0.61 0.61 0.61 0.61 0.61
aashay rashesh gogri 0.61 0.61 0.61 0.61 0.61
aashyav business trust (a... 0.04 0.04 0.04 0.04 0.04
alchemie financial servic... 0.74 0.74 0.74 0.74 0.74
alchemie finserv pvt. ltd... 0.29 0.29 0.29 0.29 0.29
anushakti enterprise priv... 3.28 3.28 3.28 3.30 3.30
arti rajendra gogri 0.52 0.52 0.52 0.50 0.50
bhanu pradip savla 0.17 0.17 0.17 0.17 0.17
bhavna family private tru... 0.89 0.89 0.89 0.89 0.89
chandrakant vallabhaji go... 0.17 0.17 0.17 0.17 0.17
dilesh roadlines pvt ltd 0.01 0.01 0.01 0.01 0.01
dinesh devchand ghalla - - - 0.11 0.11
gogri finserv pvt. ltd. 0.37 0.37 0.37 0.37 0.37
gunavanti navin shah 0.10 0.10 0.10 0.10 0.10
heena bhatia 0.36 0.36 0.36 0.36 0.36
heena family private trus... 0.92 0.92 0.92 0.92 0.92
hetal gogri gala 2.89 2.89 2.89 2.89 2.89
hetvi rohan ghalla - - - 0.17 0.17
indira madan dedhia 0.20 0.20 0.20 0.20 0.20
jasmine family trust (rel... 0.76 0.76 0.76 0.76 0.76
jaya chandrakant gogri 2.97 2.97 3.54 3.54 3.54
jayesh shah 0.02 0.02 0.02 0.02 0.02
krisha yogesh nahar - - - 0.05 0.05
labdhi business trust (sa... 3.14 3.14 3.14 3.14 3.14
lotus family trust (gloir... 0.69 0.69 0.69 0.69 0.69
mananjay singh garewal 0.18 0.18 0.18 0.18 0.18
manisha rashesh gogri 0.61 0.61 0.61 0.61 0.61
manomaya business trust (... 1.44 1.44 1.44 1.44 1.44
mirik rajendra gogri 3.08 3.08 3.08 3.08 3.08
monisha bhatia 0.13 0.13 0.13 0.13 0.13
nehal garewal 1.24 1.24 1.24 1.24 1.24
nikhil holdings private l... 0.20 0.20 0.20 0.20 0.20
nikhil parimal desai 0.85 0.85 0.85 0.79 0.75
orchid family trust (rela... 1.82 1.64 0.86 0.75 0.56
parimal hasmukhlal desai 0.44 0.44 0.44 0.39 0.39
rajendra vallabhaji gogri... 1.57 1.57 1.57 1.57 1.57
rajendra vallabhaji gogri... - - - - 0.34
rashesh chandrakant gogri... 4.23 4.23 4.23 4.23 4.23
ratanben premji gogri 0.37 0.37 0.37 0.38 0.38
renil rajendra gogri 3.08 3.08 3.08 2.81 2.81
safechem enterprises priv... 1.61 1.61 1.61 1.61 1.61
sarla shantilal shah 2.69 2.69 2.69 2.69 2.69
shantilal tejshi shah huf... - - - - 0.31
shreya suneja 0.12 0.12 0.12 0.12 0.12
tulip family trust (gloir... 1.82 1.64 0.98 0.78 0.44
valiant organics limited 0.01 0.01 0.01 0.01 0.01
rajendra vallabhaji gogri... 0.34 0.34 0.34 0.34 -
shantilal tejshi shah (hu... 0.31 0.31 0.31 0.31 -
bhavna shah lalka 0.57 0.57 - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 53.54 53.90 55.34 55.71 56.28
investor education and pr... 0.35 - - 0.35 0.34
life insurance corporatio... 6.06 6.06 6.06 6.06 6.00
llp 0.41 0.39 - 0.30 0.15
nishant pradip shah 1.10 1.10 1.10 1.10 1.10
ntasain discovery master ... 1.89 2.58 3.37 2.21 1.88
investor education and pr... - 0.35 0.35 - -
morgan stanley investment... 1.02 1.00 1.00 - -
quant mutual fund - quant... - 3.25 3.25 - -
aditya birla sun life tru... 1.05 - - - -

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q3FY24
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY23
Presentation Q3FY25
Presentation Q3FY24
Presentation Q1FY24

Company News

Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility in Gujarat 3 Sep, 4:42 PM Aarti Pharmalabs informs about annual report and AGM 29 Aug, 12:52 PM Aarti Pharmalabs - Quaterly Results 12 Aug, 7:24 PM Aarti Pharmalabs - Quaterly Results 12 Aug, 7:24 PM Aarti Pharmalabs informs about credit rating 17 Jul, 4:44 PM Aarti Pharmalabs informs about analyst meet 18 Jun, 5:12 PM Aarti Pharmalabs - Quaterly Results 10 May, 7:20 PM Aarti Pharmalabs - Quaterly Results 10 May, 7:20 PM Aarti Pharmalabs - Quaterly Results 10 May, 7:20 PM Aarti Pharmalabs informs about press release 29 Apr, 1:07 PM Aarti Pharmalab informs about board meeting 25 Apr, 11:48 AM Aarti Pharmalabs informs about compliance certificate 8 Apr, 2:04 PM Aarti Pharmalabs informs about disclosure 1 Apr, 9:50 AM Aarti Pharmalabs informs about press release 7 Feb, 2:22 PM Aarti Pharmalabs - Quaterly Results 5 Feb, 7:11 PM Aarti Pharmalabs - Quaterly Results 5 Feb, 7:11 PM Aarti Pharmalabs - Quaterly Results 5 Feb, 7:11 PM Aarti Pharmalabs informs about board meeting 28 Jan, 5:26 PM Aarti Pharmalabs informs about conference call 28 Jan, 2:30 PM Aarti Pharmalabs enters into agreement with Pro-zeal Green Power 10 Jan, 4:42 PM Aarti Pharmalabs informs about certificate 10 Jan, 12:45 PM Aarti Pharmalabs informs about updates 9 Jan, 5:28 PM Aarti Pharmalabs informs about disclosures 30 Dec, 2:51 PM Aarti Pharmalabs informs about disclosure 17 Dec, 3:58 PM Aarti Pharmalabs informs about outcome of board meeting 13 Dec, 5:04 PM Aarti Pharmalabs informs about press release 29 Oct, 11:55 AM Aarti Pharmalabs - Quaterly Results 28 Oct, 4:02 PM Aarti Pharmalabs - Quaterly Results 28 Oct, 4:02 PM Aarti Pharmalabs informs about certificate 8 Oct, 5:00 PM Aarti Pharmalabs informs about trading window closure 26 Sep, 5:29 PM Aarti Pharmalabs - Quaterly Results 5 Aug, 3:38 PM Aarti Pharmalabs - Quaterly Results 5 Aug, 3:38 PM Aarti Pharmalabs - Quaterly Results 5 Aug, 3:38 PM Aarti Pharmalabs - Quaterly Results 13 May, 5:27 PM Aarti Pharmalabs - Quaterly Results 13 May, 5:27 PM Aarti Pharmalabs - Quaterly Results 13 May, 5:27 PM Aarti Pharmalabs informs about grant of options 13 May, 5:16 PM Aarti Pharmalabs submits board meeting intimation 4 May, 3:48 PM Aarti Pharmalabs informs about certificate 4 Apr, 5:23 PM Aarti Pharmalabs - Quaterly Results 7 Feb, 4:42 PM Aarti Pharmalabs - Quaterly Results 7 Feb, 4:42 PM Aarti Pharmalabs - Quaterly Results 7 Feb, 4:42 PM Aarti Pharmalabs formally inaugurates R&D Laboratory in Nerul 19 Dec, 9:50 AM Aarti Pharmalabs - Quaterly Results 7 Nov, 6:39 PM Aarti Pharmalabs - Quaterly Results 7 Nov, 6:39 PM Aarti Pharmalabs informs about closure of trading window 28 Sep, 2:37 PM Aarti Pharmalabs informs about press release 7 Aug, 2:47 PM Aarti Pharmalabs - Quaterly Results 5 Aug, 3:52 PM Aarti Pharmalabs - Quaterly Results 5 Aug, 3:52 PM Aarti Pharmalabs - Quaterly Results 5 Aug, 3:52 PM

Aarti Pharmalabs Stock Price Analysis and Quick Research Report. Is Aarti Pharmalabs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aarti Pharmalabs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aarti Pharmalabs has a PE ratio of 31.438745154602 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aarti Pharmalabs has ROA of 10.2519% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aarti Pharmalabs has a Current ratio of 1.9488.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aarti Pharmalabs has a ROE of 14.8612%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aarti Pharmalabs has a Debt to Equity ratio of 0.2143 which means that the company has low proportion of debt in its capital.

  • Sales growth: Aarti Pharmalabs has reported revenue growth of 17.9225% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aarti Pharmalabs for the current financial year is 24.0801008585646%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aarti Pharmalabs is Rs 5 and the yield is 0.5443%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aarti Pharmalabs is Rs 28.8418. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Aarti Pharmalabs in Ticker for free. Also, one can get the intrinsic value of Aarti Pharmalabs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Aarti Pharmalabs FAQs

Q1. What is Aarti Pharmalabs share price today?
Ans: The current share price of Aarti Pharmalabs is Rs 906.75.

Q2. What is the market capitalisation of Aarti Pharmalabs?
Ans: Aarti Pharmalabs has a market capitalisation of Rs 8218.8929862 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Aarti Pharmalabs?
Ans: The PE ratio of Aarti Pharmalabs is 31.438745154602 and the P/B ratio of Aarti Pharmalabs is 4.34089489217777, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Aarti Pharmalabs share?
Ans: The 52-week high share price of Aarti Pharmalabs is Rs 971, and the 52-week low share price of Aarti Pharmalabs is Rs 557.05.

Q5. Does Aarti Pharmalabs pay dividends?
Ans: Currently, Aarti Pharmalabs pays dividends. Dividend yield of Aarti Pharmalabs is around 0.5443%.

Q6. What are the face value and book value of Aarti Pharmalabs shares?
Ans: The face value of Aarti Pharmalabs shares is Rs 5, while the book value per share of Aarti Pharmalabs is around Rs 208.8855. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Aarti Pharmalabs?
Ans: Aarti Pharmalabs has a total debt of Rs 394.8551 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Aarti Pharmalabs?
Ans: The ROE of Aarti Pharmalabs is 14.8612% and ROCE of Aarti Pharmalabs is 17.6101%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Aarti Pharmalabs a good buy for the long term?
Ans: The Aarti Pharmalabs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Aarti Pharmalabs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aarti Pharmalabs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Aarti Pharmalabs’s financials?
Ans: You can review Aarti Pharmalabs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Aarti Pharmalabs

Aarti Pharmalabs Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Aarti Pharmalabs Ltd. is a leading manufacturer of pharmaceuticals and specialty chemicals in India. The company was founded in 1984 and has since grown to become a major player in its industry. Aarti Pharmalabs operates across various segments, including active pharmaceutical ingredients, specialty chemicals, and pharma intermediates. Its wide product portfolio and diverse customer base provide the company with a competitive edge in the industry.

Aarti Pharmalabs Ltd. Share Price

Aarti Pharmalabs Ltd.'s share price is one of the critical indicators of investor sentiment towards the company. On our stock analysis page, you can find the latest share price of Aarti Pharmalabs Ltd. along with historical price charts that provide insights into the company's financial performance over time. You can also use our pre-built screening tools to compare Aarti Pharmalabs's share price with that of other companies in the same sector.

Aarti Pharmalabs Ltd. Balance Sheet

Aarti Pharmalabs Ltd.'s balance sheet is an essential financial document that shows the company's assets, liabilities, and equity at a given point in time. On our stock analysis page, you can access Aarti Pharmalabs's latest annual and quarterly balance sheets along with premium features like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help you ascertain the fair value of Aarti Pharmalabs's stock by analyzing various financial metrics such as earnings, assets, and liabilities.

Aarti Pharmalabs Ltd. Annual Report

Aarti Pharmalabs Ltd.'s annual report is a comprehensive document that provides insights into the company's financial performance, business strategy, and management outlook. On our stock analysis page, you can download Aarti Pharmalabs's latest annual reports and study its financial statements, auditor reports, and management discussion and analysis (MD&A) sections. This information can help investors make informed decisions about investing in Aarti Pharmalabs's stock.

Aarti Pharmalabs Ltd. Dividend

Aarti Pharmalabs Ltd.'s dividend payouts are an important metric to consider for long-term stock investors. On our stock analysis page, you can access Aarti Pharmalabs's latest dividend payout details, including the dividend yield, dividend history, and payout ratio. You can also compare Aarti Pharmalabs's dividend payouts with those of its peers using our pre-built screening tools.

Aarti Pharmalabs Ltd. Quarterly Result

Aarti Pharmalabs Ltd.'s quarterly results provide investors with timely updates on the company's financial performance. On our stock analysis page, you can find Aarti Pharmalabs's latest quarterly results, including its revenue, net profit, and earnings per share (EPS). You can also use our premium features like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis to analyze Aarti Pharmalabs's financial performance and estimate its fair value.

Aarti Pharmalabs Ltd. Stock Price

Aarti Pharmalabs Ltd.'s stock price is a key metric that reflects the company's market valuation. On our stock analysis page, you can access Aarti Pharmalabs's latest stock price and track its performance over time using historical price charts. You can also use our pre-built screening tools to compare Aarti Pharmalabs's stock price with that of its peers in the same industry.

Aarti Pharmalabs Ltd. Price Chart

Aarti Pharmalabs Ltd.'s price chart provides investors with a visual representation of the company's stock performance over time. On our stock analysis page, you can find Aarti Pharmalabs's latest price chart along with historical charts that cover various time periods. You can also use our pre-built screening tools to compare Aarti Pharmalabs's price chart with that of other companies in the same industry.

Aarti Pharmalabs Ltd. News

Aarti Pharmalabs Ltd.'s news section provides investors with the latest updates on the company's business activities, financial performance, and strategic initiatives. On our stock analysis page, you can access Aarti Pharmalabs's latest news articles and press releases, as well as news from various other sources. Our pre-built screening tools also help you stay up-to-date with the latest news on Aarti Pharmalabs and other companies in the same sector.

Aarti Pharmalabs Ltd. Concall Transcripts

Aarti Pharmalabs Ltd.'s concall transcripts provide investors with insights into the company's management outlook and strategy. On our stock analysis page, you can access Aarti Pharmalabs's latest concall transcripts and study the discussion between the company's management and analysts. This information can help you make informed decisions about investing in Aarti Pharmalabs's stock.

Aarti Pharmalabs Ltd. Investor Presentations

Aarti Pharmalabs Ltd.'s investor presentations provide investors with an overview of the company's financial and business performance. On our stock analysis page, you can download Aarti Pharmalabs's latest investor presentations and study its financial metrics, business strategy, and management outlook. This information can help you assess the company's growth potential and make informed decisions about investing in its stock.

Aarti Pharmalabs Ltd. Promoters

Aarti Pharmalabs Ltd.'s promoters are the individuals or entities that hold a significant stake in the company and are responsible for its management and operations. On our stock analysis page, you can access information about Aarti Pharmalabs's promoters and their shareholding patterns. This information can help you assess the company's management quality and stability and make informed decisions about investing in its stock.

Aarti Pharmalabs Ltd. Shareholders

Aarti Pharmalabs Ltd.'s shareholders are the individuals or entities that hold a stake in the company through their investment in its stock. On our stock analysis page, you can access information about Aarti Pharmalabs's shareholders and their shareholding patterns. This information can help you assess the company's investor base and make informed decisions about investing in its stock. 

Aarti Pharmalabs Balance Sheet Analysis

Aarti Pharmalabs Equity and Liabilities

The equity and liabilities of Aarti Pharmalabs have shown a significant uptrend from Mar 2020 to Mar 2024. The share capital experienced a dramatic increase from Rs 0.25 Cr in March 2020 to Rs 45.31 Cr by March 2023 and remained constant till March 2024. Total reserves, which initially recorded a negative figure in Mar 2020, escalated impressively to Rs 1,576.15 Cr by Mar 2024, indicating strong financial growth and retained earnings within the company.

Aarti Pharmalabs Assets Analysis

On the assets front, Aarti Pharmalabs have consistently increased their total assets from Rs 0.25 Cr in Mar 2020 to Rs 2,296.91 Cr by Mar 2024. Notably, the net block (physical assets) saw a significant hike, underlining the company’s expansion in its asset base to Rs 953.33 Cr by Mar 2024. Current assets have also seen a substantial rise, indicating an enhanced liquidity position of the company to Rs 1,134.06 Cr by Mar 2024.

Aarti Pharmalabs Investments and Advances

Investments and loans & advances by Aarti Pharmalabs have seen a steady rise, which showcases the company's strategic financial management and diversification. From having no investments in Mar 2020, the figure gently grew to Rs 43.83 Cr by Mar 2024, while loans & advances increased to Rs 28.77 Cr, suggesting prudent capital allocation towards growth avenues.

This data is an analysis for the Standalone Balance Sheet of Aarti Pharmalabs. Investors tracking the NSE and BSE indices might find Aarti Pharmalabs as an interesting entity due to its robust balance sheet growth and strategic asset allocation.

Read More
X